ChemoCentryx Inc  

(Public, NASDAQ:CCXI)   Watch this stock  
Find more results for CCXI
5.30
+0.05 (0.95%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.02 - 5.34
52 week 4.57 - 14.96
Open 5.29
Vol / Avg. 192,482.00/322,572.00
Mkt cap 228.81M
P/E     -
Div/yield     -
EPS -0.89
Shares 43.17M
Beta     -
Inst. own 61%
May 22, 2014
ChemoCentryx Inc Annual Shareholder Meeting - 1:00PM EDT - Add to calendar
May 12, 2014
Q1 2014 ChemoCentryx Inc Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 ChemoCentryx Inc Earnings Conference Call
Mar 13, 2014
Q4 2013 ChemoCentryx Inc Earnings Release
Mar 4, 2014
ChemoCentryx Inc at Cowen Health Care Conference
Feb 25, 2014
ChemoCentryx Inc at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1316.28% -638.17%
Operating margin -1333.93% -645.46%
EBITD margin - -635.96%
Return on average assets -24.51% -28.15%
Return on average equity -25.65% -30.25%
Employees 60 -
CDP Score - -

Address

850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
United States - Map
+1-650-2102900 (Phone)
+1-650-2102910 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company´┐Żs wholly owned subsidiary is ChemoCentryx Limited.

Officers and directors

Thomas J. Schall Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Susan M. Kanaya Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 50
Bio & Compensation  - Reuters
Juan C. Jaen Ph.D. Senior Vice President - Drug Discovery, Chief Scientific Officer
Bio & Compensation  - Reuters
Petrus J. Bekker M.D., Ph.D. Senior Vice President - Clinical and Medical Affairs
Age: 52
Bio & Compensation  - Reuters
Markus J. Cappel Ph.D. Chief Business Officer, Treasurer
Age: 52
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Ira Klein M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Geoffrey M. Parker Independent Director
Age: 48
Bio & Compensation  - Reuters
James L. Tyree Independent Director
Age: 60
Bio & Compensation  - Reuters